Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021

COVID-19 vaccine effectiveness by product (two doses Comirnaty, Spikevax or Vaxzevria and one of Janssen), against infection ranged from 50% (95% CI: 42 to 57) for Janssen to 86% (70 to 93) for Vaxzevria-Comirnaty combination; among ≥ 60 year-olds, from 17% (−26 to 45) for Janssen to 68% (48 to 80)...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez-Baz, Iván, Trobajo-Sanmartín, Camino, Miqueleiz, Ana, Guevara, Marcela, Fernández-Huerta, Miguel, Burgui, Cristina, Casado, Itziar, Portillo, María Eugenia, Navascués, Ana, Ezpeleta, Carmen, Castilla, Jesús, Martín, Carmen, Polo, Isabel, Bacaicoa, Amaya, Chamorro, Judith, Vidán, Juana, Estévez, Ingrid, Tordoya, Igberto, Quílez, Delia, Lameiro, Francisco, Álvaro, Ana Isabel, Albéniz, Esther, Echeverría, Aitziber, López Moreno, Paula, Gorricho, Javier, Ardanaz, Eva, Arriazu, Maite, Baigorria, Fernando, Barricarte, Aurelio, de la Cruz, Enrique, Díaz, Jorge, Egüés, Nerea, Cenoz, Manuel García, Iriarte, Nerea, Nekotxea, Kenya, Moreno-Iribas, Conchi, Sayón, Carmen, Tellechea, Maitane, Nuín, Marian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2021
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485582/
https://www.ncbi.nlm.nih.gov/pubmed/34596016
http://dx.doi.org/10.2807/1560-7917.ES.2021.26.39.2100894

Ejemplares similares

Ejemplares similares